Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management
March 2024
in “
Journal of Clinical Medicine
”
Studysummary In this four-year study, pediatric patients with inoperable plexiform neurofibromas and type 1 neurofibromatosis treated with selumetinib frequently experienced dermatologic side effects, which required tailored management strategies and sometimes led to treatment suspension, potentially affecting tumor regrowth.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on mdpi.com →